BSG Team Ventures has been retained to bring aboard the new CEO for a break-through approach to wound closure. The company has a patent portfolio and 4 products, two already with FDA approval, and a new Series B round of funding from passionate venture capital partners.
The addressable market is more than $5 Billion, and includes applications for plastic and reconstructive surgery, biopsy, military, perinatal, laproscopic, and other orthopedic surgical procedures.
The company is currently located in the San Francisco Bay area, California, having been founded in 2007.
Highlights of the new CEO's track record and experience will include the following:
For a more detailed outline of key success attributes, see the Venn diagram below.
For more information regarding this search, please email clark [at] bsgtv-dot-com.